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Devil facial tumor disease (DFTD) is renowned for its successful evasion of the host 
immune system. Down regulation of the major histocompatabilty complex class I 
molecule (MHC-I) on the DFTD cells is a primary mechanism of immune escape. 
Immunization trials on captive Tasmanian devils have previously demonstrated that an 
immune response against DFTD can be induced, and that immune-mediated tumor 
regression can occur. However, these trials were limited by their small sample sizes. 
Here, we describe the results of two DFTD immunization trials on cohorts of devils prior 
to their wild release as part of the Tasmanian Government’s Wild Devil Recovery project. 
95% of the devils developed anti-DFTD antibody responses. Given the relatively large 
sample sizes of the trials (N = 19 and N = 33), these responses are likely to reflect 
those of the general devil population. DFTD cells manipulated to express MHC-I were 
used as the antigenic basis of the immunizations in both trials. Although the adjuvant 
composition and number of immunizations differed between trials, similar anti-DFTD 
antibody levels were obtained. The first trial comprised DFTD cells and the adjuvant 
combination of ISCOMATRIX™, polyIC, and CpG with up to four immunizations given 
at monthly intervals. This compared to the second trial whereby two immunizations 
comprising DFTD cells and the adjuvant combination ISCOMATRIX™, polyICLC 
(Hiltonol®) and imiquimod were given a month apart, providing a shorter and, therefore, 
more practical protocol. Both trials incorporated a booster immunization given up to 
5 months after the primary course. A key finding was that devils in the second trial 
responded more quickly and maintained their antibody levels for longer compared to 
devils in the first trial. The different adjuvant combination incorporating the RNAase 
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resistant polyICLC and imiquimod used in the second trial is likely to be responsible. 
The seroconversion in the majority of devils in these anti-DFTD immunization trials was 
remarkable, especially as DFTD is hallmarked by its immune evasion mechanisms. 
Microsatellite analyzes of MHC revealed that some MHC-I microsatellites correlated to 
stronger immune responses. These trials signify the first step in the long-term objective 
of releasing devils with immunity to DFTD into the wild.
Keywords: Tasmanian devil facial tumour disease, vaccination, adjuvant, humoral immunity/antibody response, 
wild immunology
inTrODUcTiOn
The Tasmanian devil is the largest living carnivorous marsupial 
species and is unique to Australia’s island state of Tasmania. 
The species was listed as Endangered in 2008 due to mortality 
from devil facial tumor disease (DFTD) (1). DFTD is a fatal 
transmissible cancer whereby the cancer cells are the infectious 
agent and pass between individual devils by biting behavior. The 
cancer’s ability to evade the host’s immune response as it acts 
as an allograft has been the subject of ongoing research. The 
devil’s immune system has demonstrated competence from both 
humoral and cell-mediated perspectives (2–5). The DFTD cancer 
cells’ ability to avoid an allogeneic immune response is, therefore, 
not considered due to a defective devil immune system, but rather 
due to DFTD’s immune escape mechanisms (6, 7). While DFTD 
immunology and the marsupial devil immune system are in 
themselves fascinating research topics, the insights gained from 
such research have a practical application for DFTD vaccine 
development. A protective vaccine against DFTD would provide 
an extremely useful tool for managing the endangered species 
and may help prevent DFTD-driven extinction of the wild devil.
As previously mentioned, successful transmission of DFTD 
between individuals is considered to be primarily due to the 
tumor’s immune escape mechanisms. A primary mechanism 
is the down regulation of the major histocompatibility class I 
molecule (MHC-I) on the DFTD cell surface (8). Despite this, 
naturally occurring immune responses against DFTD have been 
identified in a small number of wild devils (9). Furthermore, 
immunization trials have demonstrated that humoral and cell-
mediated immune recognition of DFTD can be induced (10). 
Subsequent trials found these immune responses could lead to 
immune-mediated rejection of the tumors (11). These trials used 
DFTD cells manipulated to express surface MHC-I as the anti-
genic basis of the vaccine. This approach was intended to make 
the tumor cells immunogenic and, therefore, increase the likeli-
hood of raising both antibody and allospecific T-cell responses. 
However, limitations of these trials included small sample sizes 
and senescent individuals. The opportunity to address these 
shortcomings arose with the implementation of the Wild Devil 
Recovery project by the Tasmanian state government’s Save the 
Tasmanian Devil Program (STDP; http://www.tassiedevil.com.
au/tasdevil.nsf/Wild-Devil-Recovery/8A632773F33E4920CA
257EC9001912CE). The ongoing project involves the release of 
devils from the STDP’s captive insurance and DFTD-free island 
populations to augment local wild devil populations that have 
been decimated by DFTD.
The first wild release took place in September 2015 in 
Narawntapu National Park (NNP) in Tasmania’s north. The 
devils selected for release were held in free range enclosures 
(FREs) for several months prior to the release date and 19 were 
included in this first DFTD immunization trial. The selection of 
the immunization protocol for this trial was based on results from 
the previously mentioned trial whereby DFTD cells manipulated 
in vitro to express MHC-I on the cell surface were used as the 
antigenic basis for the immunizations.
A second release of 33 devils in Stony Head (SH) in the state’s 
north east took place in August 2016. The SH immunization 
protocol was shortened in light of the NNP trial results. It also 
incorporated an improved adjuvant combination that was identi-
fied between the NNP and SH releases (12).
Post release monitoring at NNP and SH was carried out by the 
STDP. Not all devils were trapped following release, but those that 
had serum samples collected to assess the duration of their anti-
DFTD immune responses. Booster immunizations were given to 
the SH devils that were trapped during the final month of monitor-
ing, which was 5 months after the primary immunization course.
These immunization trials provided the first opportunity to 
use comparatively large sample sizes. This meant a more robust 
assessment of anti-DFTD immune responses in Tasmanian 
devils, as determined by seroconversion, could be made. The 
responses generated by the different protocols used in the NNP 
and SH trials with respect to the number of immunizations given 
and adjuvant combination could also be compared.
Since the initiation of these trials, a second DFTD was discov-
ered (13) and named DFT2 to distinguish it from the first DFTD, 
which is now referred to as DFT1. The work described here refers 
to DFT1.
MaTerials anD MeThODs
Tasmanian Devils
There were 19 devils in the NNP trial and 33 devils in the SH trial. 
All of the NNP devils came from the captive insurance popula-
tion. Eleven of these NNP devils were originally born in the wild 
and brought into captivity at the age of 1 year (N = 10) or 2 years 
(N =  1). They were quarantined for a period of 30  months to 
ensure that they were disease free. The other eight NNP devils 
were born in captivity. Of the SH devils, 16 were born in captivity 
as part of the captive insurance population. The remaining 17 
of the SH devils were from Maria Island, the DFTD-free island 
population. See Table 1 for age and sex details of the trial devils.
Table 1 | Summary of devil age, sex, and immunization protocols for 
Narawntapu National Park (NNP) and Stony Head (SH) trials.
age 1 year 2 years 3 years 4 years 5 years Total
nnP devils
No. of males 4 0 0 7 0 11
No. of females 1 1 2 3 1 8
sh devils
No. of males 1 13 8 0 0 22
No. of females 0 1 6 4 0 11
complete nnP immunization protocol
Primary course (four immunizations given at monthly intervals)
Date of each immunization Composition of immunizationsa
1st: February 2015 2 × 107 MHC-I+ve sonicated cells
2nd: March 2015 2 × 107 MHC-I+ve sonicated cells
3rd: April 2015 2 × 106 MHC-I+ve irradiated cells
4th: May 2015 2 × 106 MHC-I+ve irradiated cells
booster immunization
Date of booster Composition of booster immunizationa
September 2015 
(pre-release)
2 × 106 MHC-I+ve irradiated cells
complete sh immunization protocol
Primary course (2 immunizations given at monthly intervals)
Date of each immunization Composition of immunizationsb
1st: June 2016 2 × 107 MHC-I+ve sonicated cells
2nd: July 2016 2 × 106 MHC-I+ve irradiated cells
booster immunization
Date of booster Composition of booster immunizationb
December 2016 (post 
release)
2 × 106 MHC-I+ve irradiated cells
aThe combination of adjuvants used in each immunization and booster was as follows: 
50 µl ISCOMATRIX™ (provided by CSL Ltd., VIC, Australia), 100 µg polyIC (Sigma-
Aldrich, P1530), 50 µg CpG-ODN-1585 (GeneWorks, 1141231), and 50 µg CpG-
ODN-2395 (GeneWorks, 1141232).
bThe combination of adjuvants used in each immunization and booster was as follows: 
50 µl ISCOMATRIX™, 100 µg polyICLC (Hiltonol®, Oncovir Inc., lot PJ215-1-10-01), 
and 100 µg Imiquimod (Sigma-Aldrich, 15159).
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Devil enclosures, Trapping, and blood 
sample collection
The NNP devils were kept in two 11 ha FREs for at least 8 months 
prior to their release. Males and females were kept separately. 
The devils were trapped fortnightly during the primary 3-month 
immunization course. Blood samples were collected each time. 
For the 4 months prior to the booster immunization, the devils 
were monitored weekly with camera traps by STDP staff. Blood 
samples were collected 2 weeks after the booster and a week later 
the devils were released. The SH devils were kept in two FRE’s, 
one 11 ha and one 22 ha, for 14 weeks prior to release, and sexes 
were not separated. They were trapped on three occasions while 
in the FRE’s for blood collection and immunization.
For each trial, not all devils were trapped each time, and 
consequently there were some differences in the immunization 
protocols given, and the blood samples available. Traps were set 
in each FRE the afternoon before procedures were performed 
(body weight, physical examination, blood collection, and 
immunization if required). The traps were baited with possum 
or lamb flaps and checked the following morning. Each trapped 
devil was transferred into a hessian sack and the handling and 
procedures were carried out by two veterinarians/devil keepers. 
General anesthesia was given in the rare event of not being able 
to handle the devil in the sack. Devils were released into the FRE 
immediately following the procedures. Blood sample collection 
and general anesthesia were performed as described in Ref. (11).
Vaccine Protocol and Preparation
Devil facial tumor disease immunizations were pre-prepared by 
treating C5065 DFTD cells with recombinant devil interferon 
gamma (IFN-γ) [produced by the Walter and Eliza Hall Institute 
for Medical Research as described in Ref. (11)] diluted 5,000× 
in culture medium for 24 h. This was to upregulate cell surface 
expression of the MHC-I molecule (8), and these cells are referred 
to as MHC-I+ve DFTD cells. The non-manipulated DFTD cells, 
i.e., cells not expressing surface MHC-I, are referred to as MHC-
I-ve DFTD cells. After treatment, MHC-I+ve DFTD cells were 
inactivated by either four ultrasonic cycles at 50% power on an 
ultrasonic cell disruptor (sonication) (Misonix Inc., Farmingdale, 
NY, USA), or by two doses of 40 Gy gamma radiation 24 h apart 
using a Varian Clinac 23-EX linear accelerator (irradiation) 
(Varian Medical Systems Inc., Palo Alto, CA, USA).
One day of travel was required prior to the administration of 
the immunizations. On the morning of the travel day, sonicated 
preparations in 1  ml phosphate buffered saline (PBS) were 
taken from −80°C, thawed and adjuvants added. Irradiated cell 
preparations were thawed, washed twice (with PBS at 500 g for 
5 min), counted and resuspended in 1 ml, and adjuvants added. 
The composition of the immunizations, including adjuvants, is 
detailed in Table 1. The immunizations were kept on ice or at 4°C 
for 24 h prior to administration. Immunizations were given as a 
subcutaneous injection between the devils’ scapulae.
serum antibody Detection
Indirect immunofluorescence and flow cytometry to measure 
serum anti-DFTD IgG antibody levels were performed on the 
serum samples against MHC-I-ve DFTD cells and MHC-I+ve 
DFTD cells. Preparation of MHC-I+ve cells was described in the 
Section “Vaccine Protocol and Preparation,” and this and the 
serum antibody detection method are also described in Ref. (11). 
In brief, DFTD cells were washed twice with PBS (500 g, 5 min). 
Pre-immune and immune serum samples were diluted 1:50 with 
washing buffer and mixed with DFTD cells for 1 h. Cells were 
washed twice with washing buffer, and incubated with 50  µl 
of 10  µg/ml of a monoclonal mouse anti-devil IgG (provided 
by the Walter and Eliza Hall Institute for Medical Research) 
for 30  min, then washed and incubated with 50  µl of 2  µg/ml 
Alexa Fluor 647 conjugated goat anti-mouse IgG antibody (Life 
Technologies, A21235) for 30  min. After washing, cells were 
resuspended in 200 µl of washing buffer containing 200 ng/ml 
of the cell viability dye 4′,6-Diamidino-2-Phenylindole, Dilactate 
(Sigma-Aldrich, D9542). Data acquisition was performed on a 
BD FACSCanto™ II flow cytometer (BD Biosciences, Franklin 
Lakes, NJ, USA). The median fluorescence intensity ratio (MFIR) 
was used to classify the antibody responses. The MFIR is defined 
as the median fluorescence intensity (MFI) of DFTD cells labeled 
with immune serum divided by the MFI of DFTD cells labeled 
FigUre 1 | Flow cytometry histograms for three individual devils showing antibodies for MHC-I-ve devil facial tumor disease cells in their pre-immune (gray) and 
post-immune (blue) serum samples. The fluorescence intensity is in log scale and shown on the x-axis, the cell count is on the y-axis. (a–c) demonstrate the range 
of responses found across the cohorts.
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with pre-immune serum. This ratio accounts for any background 
serum IgG present prior to the immunizations and standardizes 
the responses between individual devils. Examples of antibody 
staining patterns are shown in Figure 1.
Devil release and Post-release 
Monitoring
Prior to the releases, the incumbent devil populations in NNP 
and SH were each estimated at 18 individuals, with a DFTD 
prevalence of 15% (Samantha Fox, personal communication 
2016). The NNP trial devils were released on 25 September 2015. 
The monitoring trips included in this analysis were carried out 
at 2, 6, and 12 weeks post release. Serum was collected from the 
immunized devils trapped during the monitoring trips. The SH 
trial devils were released on 30 August 2016. Monitoring was car-
ried out almost continuously during the 4 months post release, 
and blood was collected when possible. A booster immunization 
was given to the SH devils that were trapped in December 2016, 
5 months after completion of the primary course.
serum antibody Data analysis of nnP and 
sh Trials
The NNP trial took place 1  year before the SH trial. The SH 
immunization protocol was, therefore, a modified version of 
the NNP protocol, based on the NNP results and the findings of 
an adjuvant trial that took place prior to the SH trial. The NNP 
protocol was longer than SH’s and so had more time points from 
which serum antibody levels were analyzed. The pre-release 
responses of the NNP and SH trials are presented here separately, 
and then compared. The post-release antibody responses of both 
trials follow.
Statistical Analysis of Serum Antibody Data
All MFIR values were log transformed prior to analysis.
A four-way repeated-measures ANOVA comparing protocol, 
age and sex over time was performed to compare antibody 
responses at three time points for the NNP trial (Figure  2). 
Repeated-measures one-way ANOVAs, paired or unpaired t-tests 
(Figures 3–6) were performed to compare overall anti-DFTD IgG 
antibody responses at different time periods. Tukey’s post hoc ana-
lyzes were performed, and for the one-way ANOVAs, multiplicity 
adjusted P values reported.
One-way ANOVAs and t-tests were performed using GraphPad 
Prism version 6 for Mac OS X, GraphPad Software, La Jolla, CA, 
USA, www.graphpad.com. The four-way ANOVA was performed 
using R statistical software (R Core Team 2014).
Mhc analysis
To determine an association between diversity at MHC-linked 
microsatellites and individual antibody score, each devil was 
screened at 12 polymorphic loci (MHC-I 01, 02, 05, 06, 07, 08, 09, 
10, 11, 12; MHC-II 02, 03) with devil specific primers (14) (Day, 
personal communication). Ear biopsies (N =  52) were stored 
in 70% ethanol at −20°C and DNA was extracted using both 
standard phenol/chloroform protocols and a PureLink Genomic 
DNA Mini Kit (Thermofisher Scientific, MA, USA). The DNA 
concentration of each sample was quantified using a Nanodrop 
2000 Spectrophotometer (Thermofisher Scientific, MA, USA) 
and samples normalized to a concentration of 10 ng/µl. Loci were 
grouped into previously formulated multiplexes (14) determined 
by the fluorescent tag on either the forward or reverse primer 
using Multiplex Manager (15).
Polymerase chain reactions (PCR) were performed using the 
Qiagen Type-it Microsatellite PCR Kit (Qiagen, CA, USA) in a 
total volume of 10 µl containing 1 × Type-it Multiplex PCR Master 
Mix (HotStarTaq Plus DNA polymerase, Type-it Microsatellite 
PCR buffer, dNTPs, 2 nM MgCl2), 0.2 µM of primer multiplex, 
and 1 µl of DNA. A negative control using water in place of DNA 
was included in each 96-well plate run. Products were amplified 
on a T100 Thermocycler (Biorad, CA, USA) following the manu-
facturer’s instructions. Amplicon products were sent to AGRF 
(Westmead, NSW, Australia) for capillary separation using an 
ABi 3130XL Genetic Analyzer (Applied Biosystems, CA, USA) 
and scored against the size ladder McLab Orange DMSO 100 
FigUre 2 | Serum anti-devil facial tumor disease IgG antibody levels (MFIR) 
for Narawntapu National Park devils showing effect of (a) protocol, (b) age, 
and (c) sex. The MFIR for each devil at each time point (2 weeks after 
primary course, on the day of the booster and 2 weeks after the booster)  
has been plotted on each graph. Protocol A = 4 immunizations at 4-week 
intervals, B = 4 immunizations at 4- or 6-week intervals, C = 3 immunizations 
at 4-week intervals, D = 2 immunizations at 2- or 4-week intervals. The p 
values for (a–c) were obtained with a four-way ANOVA analysis. See Table 3 
for detailed ANOVA results. MFIR, median fluorescence intensity ratio.
FigUre 3 | Narawntapu National Park (NNP) devils’ serum anti-devil facial 
tumor disease IgG antibody levels (MFIR). (a) Responses of devils that had 
all four immunizations in their primary course, i.e., protocol A or B, Table 2. 
Only those devils for which sera samples were available at all time points 
are included. (b) Responses of all devils for each of three time points: end 
of primary immunization course, day of booster (4 months later) and 
2 weeks post booster. Statistical analysis was performed with repeated-
measures one-way ANOVA and only significant p values are shown on the 
graphs. See Table 5 for statistical details. Pre-immune MFIR for each devil 
is equal to 1 and is, therefore, not shown. MFIR, median fluorescence 
intensity ratio.
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(Molecular Cloning Laboratories, SF). Genotypes were assigned 
to individuals via automated allele binning and confirmed visu-
ally using GeneMarker 1.95 (Soft Genetics LLC, PA, USA).
MHC Statistical Analysis
The association between antibody score and MHC marker was 
examined using multiple linear regression. Each individual was 
given a value of 0, 1, or 2 for each allele, depending on the number 
of copies of the allele that individual carried. In order to adjust 
for age, sex, and population (NNP or SH), all analyses included 
these covariates in the models. A model was fitted separately for 
each marker in MHC-I and MHC-II. The overall significance of 
a marker was obtained from a likelihood ratio test, where models 
with/without the marker in question were compared. The effect 
size of an allele on antibody score are presented as the coefficient 
from the regression model and its significance was determined 
using a Wald Test. All analyses were performed using R statistical 
software (R Core Team 2014).
FigUre 4 | Serum anti-devil facial tumor disease IgG antibody levels (MFIR) 
of Stony Head devils after their 1st and 2nd immunizations. Pre-immune 
MFIR for each devil is equal to 1 and is, therefore, not shown. MFIR, median 
fluorescence intensity ratio.
FigUre 5 | Serum anti-devil facial tumor disease (DFTD) IgG antibody 
levels [median fluorescence intensity ratio (MFIR)] of (a) Stony Head (SH) 
and Narawntapu National Park (NNP) devils 4 weeks post 1st immunization; 
(b) SH and NNP devils just at the end of their primary immunization 
courses.
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resUlTs
immunization Protocols
For the NNP trial in particular, the primary immunization protocol 
each devil received was dependent on trapping success, as well as 
the time the devils came into the trial. For example, the five juve-
niles (1-year-old devils) were late entries and, therefore, received 
only two or three initial immunizations. Table 2 summarizes the 
different NNP immunization protocols and the number of devils 
that received each one. All the NNP devils had a booster immuni-
zation 4 months after the primary course, just prior to their release.
Of the 33 SH devils, 27 had the primary immunization protocol 
as outlined in Table 1. There were six devils that had their second 
immunization on the final pre-release visit since they were not 
trapped on both the first and second visits. Consequently, there 
was no blood sample collected after their second immunization 
and so they were left out of some of the analyses.
antibody responses Prior to Wild release
The anti-DFTD IgG antibody responses were assessed separately 
against MHC-I-ve and MHC-I+ve DFTD cells. There were no 
significant differences between results for the cell types (data 
not shown), so the results presented below are responses against 
MHC-I-ve DFTD cells only. This applied to the post release analy-
sis as well. Figure 1 shows representative histograms of the flow 
cytometry data for serum samples on MHC-I-ve DFTD cells. The 
negative control for each devil is its pre-immune serum sample 
and this is compared to the post-immunization serum samples 
for each individual.
Narawntapu Trial
The effects of protocol, age, and sex on the antibody responses 
measured at three time points were assessed with a four-way 
ANOVA (Table 3). The primary immunization protocol, whether 
two, three, or four immunizations, did not make a significant 
difference to the antibody responses (Figure  2A). However, 
both age and sex were found to have significant effects on these 
(Figures 2B,C; Table 3). Juveniles had higher responses on aver-
age than adults, and females had higher responses than males.
Figure 3A shows the responses for devils that received four 
immunizations in the primary course, either protocol A or B, for 
which serum samples were available at each time point. Antibody 
levels were significantly higher after the second, third, and fourth 
immunizations compared to the first (Table 4).
Antibody levels of all devils were then compared at three 
time points: 2 weeks after the primary course; on the day of the 
booster; and 2 weeks after the booster. At the end of the primary 
immunization course, only two NNP devils failed to respond 
(MFIR <  1.5) (Figure  3B). There was a significant difference 
in MFIR over time (Table 4). The levels on average were lowest 
on the day of the booster which was 4 months after the primary 
course. The booster resulted in an increase in antibody levels 
similar to the level at the end of the primary course (Figure 3B). 
Table 3 | Results of statistical tests comparing serum antibody responses for 
(A) Figure 2.
Four-way anOVa (Figure 1. narawntapu national Park: 
effect of protocol, age, and sex on serum antibody)
df F P
Sex 1 6.609 0.028
Age 1 12.417 0.005
Protocol 3 0.682 0.583
Sex:age 1 0.348 0.569
Sex:protocol 1 0.234 0.639
Sex:time 1 3.811 0.061
Age:time 1 0 0.984
Protocol:time 3 0.820 0.494
Sex:age:time 1 1.364 0.253
Sex:protocol:time 1 0.163 0.690
Age:protocol:time 1 1.279 0.268
Error 27
FigUre 6 | Serum anti-devil facial tumor disease (DFTD) IgG antibody levels 
[median fluorescence intensity ratio (MFIR)] of (a) Narawntapu National Park 
(NNP) devils post release compared to their post booster response in 
September 2015; (b) Stony Head (SH) devils after their primary course 
compared to 5 months later; and (c) NNP and SH devils, 5 months after 
their primary immunization course, just prior to the booster administration.
Table 2 | Description of Narawntapu National Park (NNP) immunization 
protocols.
Protocol Protocol descriptiona number of devils 
receiving the protocol
A 4 immunizations at 4-week intervals:
1st and 2nd: sonicated cells
3rd and 4th: irradiated cells
6
B 4 immunizations at 4- or 6-week intervalsb:
1st and 2nd: sonicated cells
3rd and 4th: irradiated cells
6
C 3 immunizations at 4-week intervals:
1st and 2nd: sonicated cells
3rd: irradiated cells
3 (including 2 juveniles)
D 2 immunizations at 2- or 4-week intervals:
1st: sonicated cells
2nd: irradiated cells
4 (including 3 juveniles)
aSee Table 1 for complete description of immunization composition.
bTwo male devils had their 2nd immunizations 6 weeks after the 1st. There were 
4-week intervals between their 2nd and 3rd, and their 3rd and 4th immunizations. 
Four female devils had 4-week intervals between their 1st and 2nd, and 2nd and 3rd 
immunizations. The 4th immunization was given 6 weeks after the 3rd immunization. 
Juvenile = 1-year-old devil.
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A sex difference was apparent whereby post booster antibody 
levels in the adult males did not reach the levels found after the 
primary immunization course. By contrast, there was a trend for 
the booster to result in female devils having antibody levels that 
were equal to or higher than levels achieved after the primary 
course (Figure 3B; Table 5).
SH Trial
Antibody levels were significantly higher for the SH devils 6 weeks 
after the second immunization compared to 4 weeks after the first 
immunization (Figure 4; Table 4). Sex did not have a significant 
effect on the SH devils’ responses at the end of their primary 
immunization course. There was only one juvenile devil in the 
SH trial so a comparison between juvenile and adult responses 
was not possible.
Table 4 | Results of statistical tests comparing serum antibody responses for 
(B) Figures 3–6.
repeated-measures anOVa
Figure df F P adjusted P values 
for multiple 
comparisons 
(not shown on 
graphs)
columnsa P
3 (A) NNP devils that received 
protocol A or B
3 18.10 0.001 B–C 0.067
B–D 0.072
C–D 0.543
3 (B) NNP, both sexes 2 7.061 0.005 A–C 0.986
3 (B) NNP, males 2 19.190 <0.001 A–B 0.004
A–C 0.035
B–C 0.003
3 (B) NNP, females 2 9.552 0.008 A–B 0.257
A–C 0.071
B–C 0.003
6 (A) NNP, post release compared 
to post boosterb
2 2.200 0.223 A–B 0.976
A–C 0.200
B–C 0.199
Figure df t P
Paired t-test
4. SH after 1st and 2nd 
immunizations, both sexes
26 5.438 <0.001
4. SH males 19 4.798 <0.001
4. SH females 6 2.405 0.053
6 (B) SH, post primary course 
compared to time of booster
12 1.480 0.165
Unpaired t-test
5 (A) SH and NNP, 4 weeks post 
1st immunization
49 5.713 <0.001
5 (B) SH and NNP after primary 
immunization course
38 2.600 0.013
6 (C) NNP and SH just prior to 
booster administration
26 2.540 0.017
aA, B, C, and D refer to columns in the graphs, i.e., A, 1st column, B, 2nd column;  
C, 3rd column; D, 4th column.
bOnly 3 time points compared statistically due to missingness.
NNP, Narawntapu National Park trial; SH, Stony Head trial.
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Comparison of SH and NNP Trials
The only directly comparable time point for the NNP and SH 
trials was 4  weeks after the first immunization. The SH devils 
had significantly higher serum antibody levels than NNP devils 
(Figure 5A; Table 4). At the end of the primary course, the NNP 
devils that had three or four immunizations had higher serum 
antibody levels than the SH devils (Figure 5B; Table 4).
A the end of their primary course, 17 of the 19 NNP devils, 
and all 33 of the SH devils had seroconverted providing an overall 
percentage of 96% for seroconversion in response to the DFTD 
immunizations.
antibody responses after Wild release
Following the release into NNP, monitoring trips included in this 
analysis were carried out at 2, 6, and 12 weeks. There were six devils 
trapped on the first post monitoring trip, and only three devils at 
12 weeks. There was a trend for antibody levels to decrease over 
this time to almost baseline levels at 12 weeks (Figure 6A; Table 4).
Monitoring at SH was carried out almost continuously for 
4 months post release, i.e., up until 5 months after the primary 
course. There were 17 devils that were trapped, had blood collected, 
and given a booster immunization in the final month of monitor-
ing. Of these devils, 13 had blood samples collected 6 weeks after 
their second immunization. Antibody levels were maintained by 
these 13 devils over the 5-month period between their second 
immunization and booster (Figure 6B; Table 4). This contrasts 
with the NNP devils whose antibody levels dropped over a similar 
time frame (Figure 2B, 2 weeks post primary course compared 
to at time of booster). Five months after the primary course, the 
SH devils, which all received a total of two immunizations, had 
a higher overall antibody level than the NNP devils which had 
received three or four immunizations (Figure 6C; Table 4).
Mhc Microsatellites Markers
Microsatellites across the MHC-I and MHC-II were compared 
to the antibody responses (MFIR). Highly significant (p < 0.005) 
associations occurred between antibody responses and MHC-
I_10, and a significant association (p < 0.05) was identified for 
MHC-I_02 and MHC-I_08 (Table 5). No significant associations 
were found with MHC-I loci 01, 05, 06, 07, and 11. There was lim-
ited diversity across MHC-II loci (02 and 03) and no associations 
were identified. The significance of the effect of each MHC-I and 
MHC-II microsatellite markers on serum antibody are shown in 
Table S1 in Supplementary Material.
The statistical analysis of the MHC data and its association with 
antibody response was adjusted for age, sex, and population (NNP 
or SH). A significant effect of age on antibody score was dem-
onstrated, with an average decrease in antibody score of 0.76 for 
every year of a devil’s life (p < 0.001). There were non-significant 
effects observed for population (NNP devils having an antibody 
score of 0.12 greater than SH devils, p = 0.77) and sex (females 
having an antibody score of 0.1 greater than males, p = 0.81).
The DFTD tumor cell line used in the immunizations was 
assessed for the presence of microsatellites. None of the three 
alleles associated with a higher antibody response were present in 
the C5065 cell line that was used for the immunizations (Table 5).
DiscUssiOn
These trials brought about the first cohorts of devils immunized 
against DFTD and released to the wild in the STDP’s Wild Devil 
Recovery project. The collaboration combined two innovative 
management strategies to prevent the extinction of devils in the 
wild: DFTD immunization and population augmentation. The 
immunization trials were performed on a much larger number 
of devils than had previously been possible, allowing for a robust 
assessment of the induced immune responses. The two trials 
differed with respect to the number and timing of the immuniza-
tions given in the primary course, and the adjuvant combination.
There are other examples of vaccinating captive bred and/or 
wild populations of endangered species against fatal diseases, e.g., 
black-footed ferrets against plague and canine distemper virus 
Table 5 | Devil MHC microsatellite markers that have alleles significantly associated with a high antibody response.
Mhc 
marker
P-value of marker 
(adjusted for age, 
sex, and population)
allele effect size P-value of allele (adjusted for 
age, sex, and population)
Mean antibody score (median fluorescence 
intensity ratio), and number of devils  
with 1 or 2 copies of the allele
Vaccine cell 
line alleles
MHC-I 02 0.041a 201 0.56 0.048a 3.5, N = 20 /
203 NA NA 2.9, N = 40 203, 203
MHC-I 08 0.029a 216 0.95 0.195 2.5, N = 23 /
218 1.91 0.054 3.3, N = 3 /
220 1.4 0.069 3.2, N = 20 220
222 1.73 0.030a 3.5, N = 17 /
224 NA NA 1.8, N = 3 224
MHC-I 10 0.003a 243 3.37 0.039a 6.4, N = 1 /
245 0.71 0.535 3.3, N = 33 /
247 0.09 0.938 2.5, N = 27 /
249 NA NA 1.8, N = 1 249
251 NA NA N = 0 251
Models were adjusted for age, sex, and population. Age was found to have a significant association with antibody response. The alleles of the MHC markers significantly associated 
with high serum antibody are also shown, along with their P values. The effect size indicates the average increase in serum antibody observed for each copy of the allele. P values for 
alleles were obtained from a likelihood ratio test/Wald test, respectively. The last column shows the alleles of the C5065 cell line used in the vaccine.
aIndicates significance.
NA = not available; / = none shared with respect to MHC allele.
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to the wider devil population due to the small sample sizes. The 
high number of responders in these trials suggests most devils are 
capable of producing an immune response against DFTD which 
is encouraging for vaccine development.
MHC-linked microsatellite analysis of the immunized devils 
showed that particular MHC alleles were associated with a higher 
antibody response to the immunizations. These alleles were not 
present in the tumor cell line that was used as the basis of the immu-
nization. This suggests that the MHC type of the individual devil 
may influence its response to DFTD immunizations. It also implies 
that an immune response against DFTD is more likely if the MHC 
of the devil and the tumor are mismatched. However, there is no 
evidence in the literature that MHC type affects devil responses to 
naturally occurring DFTD infection (24, 25). Sequencing analysis 
of the MHC genes themselves and their expression may provide 
further insight into the relationship between MHC and a devil’s 
ability to respond to immunization. IgG responses in both NNP 
and SH trials were specific for both non-manipulated and MHC-I 
upregulated DFTD cells, suggesting that immune responses 
against DFTD surface antigens other than MHC were generated. 
These responses will be critical for recognition of MHC-I-ve DFTD 
cells upon exposure to the disease in the wild.
The statistical analysis of the MHC data and its association with 
antibody response found a significant effect of age. This result is 
in accordance with previous research showing the decline of the 
devil’s immune capacity with age (26). The NNP trial included 
five juvenile devils which allowed for the effect of age (juvenile 
compared to adult) on the immune response to be assessed. The 
juveniles showed, on average, higher antibody responses than 
the adult devils. This was despite the juveniles receiving fewer 
immunizations in the primary course than the majority of adults. 
Only one juvenile was in the SH trial, which precluded a compari-
son between juvenile and adult responses. The NNP trial showed 
female devils to have significantly higher antibody responses than 
males. There was no overall significant sex difference found in the 
(16, 17), kakapo against erysipelas (18), and Ethiopian wolves 
against rabies (19, 20). An experimental chlamydia vaccine trial 
has also been carried out on a wild population of koalas in south 
east Queensland (21). The DFTD immunization trials shared 
aspects of these examples, notably a focus on an endangered spe-
cies facing a primary threat of disease which might be addressed 
by vaccination. However, most of the previous examples are 
against microorganisms for which vaccines have been established.
A vaccine protecting against DFTD would be a valuable con-
servation tool to secure the future of the wild devil population. 
There are suggestions that responses to DFTD are occurring in the 
wild. Natural immune responses against DFTD have been found 
in a small percentage of wild devils (9). There is also evidence that 
genetic selection associated with DFTD has occurred in certain 
populations (22). However, there has not been a measurable 
reduction of the DFTD effect on these populations. DFTD has 
resulted in dramatic devil population decline to the point where 
the species is functionally extinct in certain locations (23). Even 
with the assumption that adequate anti-DFTD responses are 
evolving, the ecological impacts of a decimated devil population 
are profound and relying on natural selection of resistant animals 
for population recovery at this stage seems risky. A protective 
DFTD vaccine would aid in timelier restoration of a functional 
devil population while helping to ensure maintenance of the 
genetic diversity of the species.
With respect to DFTD vaccine development, the biggest 
advantage of the trials described in this study was the sample 
size. Previous immunization studies have been carried out on a 
maximum of four devils at a time. The comparatively large sample 
sizes here allowed for greater confidence in the assessment of 
anti-DFTD immune responses. It also allowed for the effects of 
age, sex, differing immunization protocols, and MHC variation 
to be evaluated. Prior immunization trials on captive devils have 
demonstrated that an immune response against DFTD is achiev-
able. However, it was unknown if results could be generalized 
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SH trial. SH males did, however, show a significant increase in 
antibody levels after their second immunization, whereas there 
was only a trend for antibody levels to increase in the females. 
There is evidence that sex affects immune responses via a com-
bination of genetic, hormonal, and environmental factors with 
human studies generally showing females to have heightened 
immunity to pathogens, and a tendency toward higher responses 
to bacterial and viral vaccines than males (27).
Compared to conventional immunization protocols against 
microbial pathogens, the NNP immunization protocol was long, 
taking 7 months including the booster prior to the release date. 
Not all devils received the entire primary immunization course, 
and results suggested that a reduced number of primary immu-
nizations did not affect the post booster antibody response. This 
evidence that similar antibody responses could be achieved with 
fewer immunizations was used to refine the protocol for the SH 
trial. Similarly, results from an adjuvant study on captive devils 
that took place prior to the SH trial influenced the choice of 
adjuvant used in the SH protocol (12). A shorter and, therefore, 
more practical protocol with a promising adjuvant combination 
was implemented for SH. Both the NNP and SH trials resulted in 
similar levels of serum antibody. The improvements identified in 
the SH trial were that antibody levels were achieved more rapidly 
and were of longer duration. Following their first immuniza-
tion, the SH devils had higher overall antibody levels than the 
NNP devils. These levels in the SH devils were maintained over 
the 5 months prior to the booster compared to the NNP devils 
which had a significant decline in antibody levels pre-booster. 
In addition, the NNP devils trapped 3 months after release had 
antibody levels approaching baseline. This suggests that superior 
immune memory was stimulated in the SH devils. It is likely that 
the adjuvant combination used in the SH trial was responsible for 
the improved speed and duration of response.
The adjuvant component in both trials included 
ISCOMATRIX ™, a proprietary saponin-based adjuvant which has 
previously been shown to generate antigen-specific CD8+ T cells 
and result in regression of established solid tumors when combined 
with toll-like receptor (TLR) agonists (28). The adjuvant component 
of the NNP and SH trials differed in their use of TLR agonists. The 
NNP trial included the TLR9 agonist, CpG- oligodeoxynucleotide 
(CpG), and the TLR3 agonist, polyinosinic:polycytidylic acid 
(polyIC). This combination was in keeping with the DFTD immu-
nization trials that documented tumor regression (11).
As mentioned above, a study was undertaken prior to the SH trial 
to assess adjuvant effects on the immune responses of devils to the 
model antigen, keyhole limpet hemocyanin (KLH) (12). The study 
used the TLR-7 agonist imiquimod, and polyICLC (Hiltonol®) 
which is more stable than polyIC due to its ribonuclease resistance. 
Imiquimod alone resulted in a minimal immune response to KLH. 
PolyICLC, however, gave a robust antibody response when used 
alone and also in combination with imiquimod. In light of these 
results, the SH trial protocol omitted CpG and replaced it with 
imiquimod, and the polyIC was replaced with polyICLC.
As discussed in Patchett et al. (12), polyICLC and imiquimod 
activate potent antigen-specific immunity through the stimula-
tion of multiple immune pathways in human and animal studies. 
PolyIC results in production of large amounts of type-1 IFN. 
In mice immunized with polyICLC, substantial increases in 
CD8+ T-cell cytotoxicity occurred (29, 30). Imiquimod is also a 
potent stimulator of type-1 IFN via TLR-7-dependent activation 
of plasmacytoid dendritic cells (pDCs) (31). Previous studies 
of adjuvant efficacy have demonstrated improved generation of 
T-cell memory in response to polyICLC or imiquimod compared 
to other adjuvants (32, 33). Similar responses in Tasmanian devils 
to DFTD immunizations containing polyICLC may offer a greater 
likelihood of protection against DFTD.
There were two notable limitations to these trials. The first was 
the inability to measure the cell-mediated immune response to the 
immunizations due to the absence of a reliable cytotoxicity assay. 
The challenges of designing and implementing accurate T-cell 
assays in human clinical trials are substantial and well reviewed 
(34). Furthermore, in vitro evidence for specific T-cell responses 
does not always predict vaccine-mediated protection and Saade 
et al. highlight the need for better correlates of vaccine-induced 
T-cell immunity.
Here, serum IgG antibodies specific for DFTD were used to 
measure the responses induced by the immunizations (11). Since 
IgG production is T cell dependent, this provides indirect evidence 
for T-cell involvement. Previous research has suggested that a 
humoral immune response can inhibit development of a protective 
cellular immune response (35), the latter being requisite for a can-
cer vaccine. However, the correlation between anti-DFTD serum 
antibodies and DFTD regression has been documented in both 
wild and captive devils (9, 11) indicating the relevance of serum 
antibodies in an anti-DFTD response. As was postulated in these 
references, antibody-dependent cell-mediated cytotoxicity is a 
mechanism by which antibodies could facilitate tumor cell killing.
Another limitation associated with the trials was the low post-
release trapping success of immunized devils. This applied par-
ticularly to the NNP trial. The low NNP recapture rate was partly 
due to the devils’ likely dispersal beyond the trap lines, but also 
due to deaths from road traffic accidents (36). Trapping at SH was 
more successful due to the SH devils being fitted with GPS collars 
just prior to their release. The devils were, therefore, trackable 
until the collars were removed within 4 months of release, and it 
was possible to collect serum from 17 SH devils 4 months after 
the release date. Future trapping success will dictate whether the 
duration of antibody responses and the effect of the immunization 
protocol on DFTD susceptibility can be confidently ascertained. 
At the time of publication, three of the devils released at SH have 
been confirmed positive for DFTD due to natural exposure. 
Longitudinal sample collection and analysis are required before 
drawing conclusions on whether the immunization responses 
influence tumor growth rate in the devils that acquire disease.
Despite the limitations, these trials signify a notable advance 
in DFTD vaccine research. Although it remains unclear what 
protection the immunization protocols provided against a natural 
DFTD challenge, the serum antibodies detected in the majority 
of devils in response to the immunizations suggest that devel-
opment of an effective DFTD vaccine is a realistic expectation. 
The improved antibody response obtained with the shorter proto-
col used in the SH trial was most likely a function of the adjuvant 
used and was a particularly encouraging finding for the eventual 
feasibility of an immune solution to DFTD.
11
Pye et al. Immunization Strategies against DFTD
Frontiers in Immunology | www.frontiersin.org February 2018 | Volume 9 | Article 259
eThics sTaTeMenT
All procedures were approved by the University of Tasmania 
Animal Ethics Committee (permit number A0014599). Permission 
to obtain samples was approved by the Tasmanian Department of 
Primary Industries, Parks, Water and Environment (DPIPWE) 
for the period 20 September 2016 to 19 September 2021 inclusive.
aUThOr cOnTribUTiOns
The field work and experiments were conceived and designed by 
RP, AM, AS, MP, AK, SF, CH, GW, AL, DP, and LC. The labora-
tory experiments were performed by RP, AP, and EM. The data 
was analyzed by EM, RT, SC, AP, RP, KB, CH, GW, and AL. The 
manuscript was written by RP, GW, and AL. All authors approved 
the manuscript.
acKnOWleDgMenTs
Judy Clarke and Save the Tasmanian Devil Program staff; Jocelyn 
Darby and the Tasmanian devil immunology research group, 
Menzies Institute for Medical Research; Tasmania Zoo; East 
Coast Nature World; the Holman Clinic, Royal Hobart Hospital; 
Tasmania Parks and Wildlife Service; Saffire; Dr. Andres Salazar, 
Oncovir (Washington DC). We acknowledge suggestions from, 
Jim Kaufman (University of Cambridge), Hannah Siddle 
(University of Southampton), Wilf Jefferies (University of British 
Columbia), James Murphy (Walter and Eliza Institute for Medical 
Research).
FUnDing
This work was supported by the Australian Research Council 
[LP130100218; LP140100508]; and the University of Tasmania 
Foundation through funds raised by the Save the Tasmanian Devil 
Program Appeal and Wildcare Inc. The Wild Devil Recovery 
Project received funding from the Australian Commonwealth 
and Tasmanian State Governments.
sUPPleMenTarY MaTerial
The Supplementary Material for this article can be found online at 
http://www.frontiersin.org/articles/10.3389/fimmu.2018.00259/
full#supplementary-material.
reFerences
1. Hawkins CE, McCallum H, Mooney N, Jones M, Holdsworth M. 
Sarcophilus harrisii. In IUCN Red List of Threatened Species Version 2016-2. 
e.T40540A10331066 ed. International Union for the Conservation of Nature 
(2008).
2. Kreiss A, Fox N, Bergfeld J, Quinn SJ, Pyecroft S, Woods GM. Assessment 
of cellular immune responses of healthy and diseased Tasmanian devils 
(Sarcophilus harrisii). Dev Comp Immunol (2008) 32:544–53. doi:10.1016/j.dci. 
2007.09.002 
3. Kreiss A, Wells B, Woods GM. The humoral immune response of the 
Tasmanian devil (Sarcophilus harrisii) against horse red blood cells. Vet 
Immunol Immunopathol (2009) 130:135–7. doi:10.1016/j.vetimm.2009.02.003 
4. Brown GK, Kreiss A, Lyons AB, Woods GM. Natural killer cell mediated 
cytotoxic responses in the Tasmanian devil. PLoS One (2011) 6:e24475. 
doi:10.1371/journal.pone.0024475 
5. Kreiss A, Cheng Y, Kimble F, Wells B, Donovan S, Belov K, et al. Allorecognition 
in the Tasmanian devil (Sarcophilus harrisii), an endangered marsupial species 
with limited genetic diversity. PLoS One (2011) 6:e22402. doi:10.1371/journal.
pone.0022402 
6. Woods GM, Howson LJ, Brown GK, Tovar C, Kreiss A, Corcoran LM, et al. 
Immunology of a transmissible cancer spreading among Tasmanian devils. 
J Immunol (2015) 195:23–9. doi:10.4049/jimmunol.1500131 
7. Pye RJ, Woods GM, Kreiss A. Devil facial tumor disease. Vet Pathol (2015) 
53(4):726–36. doi:10.1177/0300985815616444 
8. Siddle HV, Kreiss A, Tovar C, Yuen CK, Cheng Y, Belov K, et al. Reversible 
epigenetic down-regulation of MHC molecules by devil facial tumour disease 
illustrates immune escape by a contagious cancer. Proc Natl Acad Sci U S A 
(2013) 110:5103–8. doi:10.1073/pnas.1219920110 
9. Pye R, Hamede R, Siddle HV, Caldwell A, Knowles GW, Swift K, et  al. 
Demonstration of immune responses against devil facial tumour disease in 
wild Tasmanian devils. Biol Lett (2016) 12(10):5. doi:10.1098/rsbl.2016.0553 
10. Kreiss A, Brown GK, Tovar C, Lyons AB, Woods GM. Evidence for induction of 
humoral and cytotoxic immune responses against devil facial tumor disease cells 
in Tasmanian devils (Sarcophilus harrisii) immunized with killed cell prepara-
tions. Vaccine (2015) 33(26):3016–25. doi:10.1016/j.vaccine.2015.01.039 
11. Tovar C, Pye RJ, Kreiss A, Cheng Y, Brown GK, Darby J, et  al. Regression 
of devil facial tumour disease following immunotherapy in immunised 
Tasmanian devils. Sci Rep (2017) 7:43827. doi:10.1038/srep43827 
12. Patchett AL, Tovar C, Corcoran LM, Lyons AB, Woods GM. The toll-like 
receptor ligands Hiltonol(R) (polyICLC) and imiquimod effectively acti-
vate antigen-specific immune responses in Tasmanian devils (Sarcophilus 
harrisii). Dev Comp Immunol (2017) 76:352–60. doi:10.1016/j.dci.2017. 
07.004 
13. Pye RJ, Pemberton D, Tovar C, Tubio JM, Dun KA, Fox S, et  al. A second 
transmissible cancer in Tasmanian devils. Proc Natl Acad Sci U S A (2016) 
113:374–9. doi:10.1073/pnas.1519691113 
14. Cheng Y, Belov K. Isolation and characterisation of 11 MHC-linked micro-
satellite loci in the Tasmanian devil (Sarcophilus harrisii). Conserv Genet 
Resour (2011) 4:463–5. doi:10.1007/s12686-011-9575-4 
15. Holleley CE, Geerts PG. Multiplex manager 1.0: a cross-platform computer 
program that plans and optimizes multiplex PCR. Biotechniques (2009) 
46:511–7. doi:10.2144/000113156 
16. Marinari PE, Kreeger JS. An adaptive management approach for black-footed 
ferrets in captivity. In: Roelle JE, Miller BJ, Godbey JL, Biggins DE, editors. 
Recovery of the Black-Footed Ferret: Progress and Continuing Challenges. U.S. 
Geological Survey Scientific Investigations Report 2005–5293 (2006). 288 p.
17. US Fish and Wildlife Service. Recovery Plan for the Black-Footed Ferret 
(Mustela nigripes). Wellington, CO: U.S. Fish and Wildlife Service (2013).
18. Gartrell BD, Alley MR, Mack H, Donald J, Mcinnes K, Jansen P. Erysipelas in 
the critically endangered kakapo (Strigops habroptilus). Avian Pathol (2005) 
34:383–7. doi:10.1080/03079450500268583 
19. Randall DA, Williams SD, Kuzmin IV, Rupprecht CE, Tallents LA, Tefera Z, 
et  al. Rabies in endangered Ethiopian wolves. Emerg Infect Dis (2004) 
10:2214–7. doi:10.3201/eid1012.040080 
20. Sillero-Zubiri C, Marino J, Gordon CH, Bedin E, Hussein A, Regassa F, et al. 
Feasibility and efficacy of oral rabies vaccine SAG2 in endangered Ethiopian 
wolves. Vaccine (2016) 34:4792–8. doi:10.1016/j.vaccine.2016.08.021 
21. Waugh C, Khan SA, Carver S, Hanger J, Loader J, Polkinghorne A, et  al.  
A prototype recombinant-protein based Chlamydia pecorum vaccine results 
in reduced chlamydial burden and less clinical disease in free-ranging koalas 
(Phascolarctos cinereus). PLoS One (2016) 11:e0146934. doi:10.1371/journal.
pone.0146934 
22. Epstein B, Jones M, Hamede R, Hendricks S, Mccallum H, Murchison EP, 
et  al. Rapid evolutionary response to a transmissible cancer in Tasmanian 
devils. Nat Commun (2016) 7:12684. doi:10.1038/ncomms12684 
23. Hollings T, Mccallum H, Kreger K, Mooney N, Jones M. Relaxation of 
risk-sensitive behaviour of prey following disease-induced decline of an apex 
12
Pye et al. Immunization Strategies against DFTD
Frontiers in Immunology | www.frontiersin.org February 2018 | Volume 9 | Article 259
predator, the Tasmanian devil. Proc Biol Sci (2015) 282:20150124. doi:10.1098/
rspb.2015.0124 
24. Wright B, Willet CE, Hamede R, Jones M, Belov K, Wade CM. Variants in the 
host genome may inhibit tumour growth in devil facial tumours: evidence 
from genome-wide association. Sci Rep (2017) 7:423. doi:10.1038/s41598- 
017-00439-7 
25. Lane A, Cheng Y, Wright B, Hamede R, Levan L, Jones M, et al. New insights 
into the role of MHC diversity in devil facial tumour disease. PLoS One (2012) 
7:e36955. doi:10.1371/journal.pone.0036955 
26. Cheng Y, Heasman K, Peck S, Peel E, Gooley RM, Papenfuss AT, et  al. 
Significant decline in anticancer immune capacity during puberty in the 
Tasmanian devil. Sci Rep (2017) 7:44716. doi:10.1038/srep44716 
27. Klein SL, Flanagan KL. Sex differences in immune responses. Nat Rev Immunol 
(2016) 16:626–38. doi:10.1038/nri.2016.90 
28. Silva A, Mount A, Krstevska K, Pejoski D, Hardy MP, Owczarek C, et al. The 
combination of ISCOMATRIX adjuvant and TLR agonists induces regres-
sion of established solid tumors in  vivo. J Immunol (2015) 194:2199–207. 
doi:10.4049/jimmunol.1402228 
29. Cho HI, Barrios K, Lee YR, Linowski AK, Celis E. BiVax: a peptide/poly-IC 
subunit vaccine that mimics an acute infection elicits vast and effective anti- 
tumor CD8 T-cell responses. Cancer Immunol Immunother (2013) 62:787–99. 
doi:10.1007/s00262-012-1382-6 
30. Kato H, Takeuchi O, Sato S, Yoneyama M, Yamamoto M, Matsui K, et  al. 
Differential roles of MDA5 and RIG-I helicases in the recognition of RNA 
viruses. Nature (2006) 441:101–5. doi:10.1038/nature04734 
31. Gibson SJ, Lindh JM, Riter TR, Gleason RM, Rogers LM, Fuller AE, et  al. 
Plasmacytoid dendritic cells produce cytokines and mature in response to the 
TLR7 agonists, imiquimod and resiquimod. Cell Immunol (2002) 218:74–86. 
doi:10.1016/S0008-8749(02)00517-8 
32. Goldinger SM, Dummer R, Baumgaertner P, Mihic-Probst D, Schwarz K, 
Hammann-Haenni A, et  al. Nano-particle vaccination combined with 
TLR-7 and -9 ligands triggers memory and effector CD8(+) T-cell responses 
in melanoma patients. Eur J Immunol (2012) 42:3049–61. doi:10.1002/
eji.201142361 
33. Martins KA, Cooper CL, Stronsky SM, Norris SL, Kwilas SA, Steffens JT, 
et al. Adjuvant-enhanced CD4 T cell responses are critical to durable vaccine 
immunity. EBioMedicine (2016) 3:67–78. doi:10.1016/j.ebiom.2015.11.041 
34. Saade F, Gorski SA, Petrovsky N. Pushing the frontiers of T-cell vaccines: 
accurate measurement of human T-cell responses. Expert Rev Vaccines (2012) 
11:1459–70. doi:10.1586/erv.12.125 
35. Hamilton DH, Bretscher PA. Different immune correlates associated with 
tumor progression and regression: implications for prevention and treatment of 
cancer. Cancer Immunol Immunother (2008) 57:1125–36. doi:10.1007/s00262- 
007-0442-9 
36. Grueber CE, Reid-Wainscoat EE, Fox S, Belov K, Shier DM, Hogg CJ, et al. 
Increasing generations in captivity is associated with increased vulnerability of 
Tasmanian devils to vehicle strike following release to the wild. Sci Rep (2017) 
7:2161. doi:10.1038/s41598-017-02273-3 
Conflict of Interest Statement: The authors declare that the research was con-
ducted in the absence of any commercial or financial relationships that could be 
construed as a potential conflict of interest.
Copyright © 2018 Pye, Patchett, McLennan, Thomson, Carver, Fox, Pemberton, 
Kreiss, Baz Morelli, Silva, Pearse, Corcoran, Belov, Hogg, Woods and Lyons. This is an 
open-access article distributed under the terms of the Creative Commons Attribution 
License (CC BY). The use, distribution or reproduction in other forums is permitted, 
provided the original author(s) and the copyright owner are credited and that the 
original publication in this journal is cited, in accordance with accepted academic 
practice. No use, distribution or reproduction is permitted which does not comply 
with these terms.
